The issue of Access to Medicine has recently been supported by the World Health Organization and international non-profit organizations. Their primary objective is to promote global access to safe, effective, and affordable medicines for all mankind, encompassing aspects such as drug R&D, production, distribution, and ensuring accessibility. Oneness Biotech is committed to developing innovative drugs to create a healthy life for mankind. The ultimate goal of our access to medicine strategy is to enable patients to obtain the medicine they need in a reasonable, affordable, correct, and easy accessibility, so as to strengthen the resilience of health of the global medical care system. Therefore, we have integrated the three major strategies: “Research and Development”, “Accessibility of Medicaments”, and “Affordability of Medicaments”.
Research and Development
Successful pharmaceutical technology research and development will help elevate the industry standard of drug R&D and manufacturing. At the same time, ensuring the quality of clinical trials will help to promote more effective and safe drugs to enter the market. Through innovative R&D breakthroughs, more effective treatment methods are discovered for Unmet Medical Needs. This continuous enhancement of value of new drug development provides patients with more effective and precise treatment options.
Education and Training of Medical Staff
Continuous Professional Development (CPD) enables medical staff to constantly update and expand their professional knowledge and skills. In line with this, Oneness plans educational training for medical staffs regarding new drugs to enhance their understanding of these medications, thereby promoting healthcare quality and patient safety. In 2024, the Company partnered with the Taiwan Society of Wound Care to organize online forums on wound care. Experienced professional nurses were invited to share their practical wound care experience and to discuss the latest wound treatment technologies and care trends. A total of 4 online forums were held throughout the year, with the number of trainees exceeding 1,000 nursing personnel.
Industry-University-Institute Collaboration Plans
The program was used for collaboration between the medical field, academia, and research institutes. The goal was to gain a deeper understanding of various drug mechanisms and the expansion of possible indications through participation in academic and clinical research. In 2024, a total of 2 research projects were in the implementation phase.
International Journal Publications
Publishing in international journals is an effective way to engage with the global academic community. We can share the results of new drug research results through these papers and promote collaboration opportunities that may include cross-border clinical trials and research collaborations. Therefore, Oneness aims to strengthen the academic research of the Company's new drugs by submitting to internationally renowned scientific journals. Its value and international popularity have been published in internationally renowned journals.
In 2024, Oneness participated in two international medical conferences held in the United States and Taiwan, presenting a total of 3 posters. These presentations shared clinical case studies highlighting the therapeutic potential and innovative clinical strategies of ON101® cream in the treatment of diabetic foot ulcers. In addition, to demonstrate the clinical efficacy of ON101® cream, Oneness published 4 articles in international scientific journals in 2024. These publications underscored the significant effectiveness of ON101® in promoting the healing of various chronic wounds, representing a meaningful contribution to improving patients' quality of life.
Note: For detailed information on annual conferences and journal publications, please refer to the Company's Website/ Science/ R&D/ Research Publication
Accessibility of Medicaments
Unequal treatment of access to medicine is a global sustainability issue, and we take the health and well-being of mankind as our core responsibility. Therefore, we have proposed multiple access solutions for drugs. We look forward to providing drugs promptly to patients in need, regardless of their location. Through innovative cross-border collaboration projects, we aim to enable patients in developing and underdeveloped countries to access medication in advance, thus enhancing the well-being of disadvantaged patients and strengthening the integrity of their healthcare system. Since 2023, Oneness has launched the “Bonvadis® Global Testing Program” to expand the application of our Bonvadis® Cream. Additionally, to provide patients in low- to middle-income countries with early access to the medication, the Company plans to expand its reach in 2024 beyond the United States, Egypt, and India to include additional priority countries such as Pakistan and several others in the Middle East.
Expanded Access Program
In accordance with the policy of the U.S. Food and Drug Administration (FDA), "Expanded Access Program" , to provide patients with investigational products for treatment when they cannot obtain comparable or satisfactory alternative treatments.
Bonvadis® Global Testing Program
Launched in 2023, the Bonvadis® Global Testing Program has been initiated in United States, Egypt, India, Pakistan, and several across the Middle East with key opinion leaders. Samples of Bonvadis® Cream have been provided to the physicians to enable collection of user’s experience and feedback. This will be helpful to position Bonvadis® Cream right in the clinical use and maximize its benefit to patients after commercial launch. This program also help address the more vulnerable or underserved patients who can’t access effective treatments. In 2023, a total of 270 Bonvadis® Cream were donated to 12 medical institutions globally, benefiting 63 patients. In 2024, the program was extended to 19 international partner healthcare institutions, distributing a total of 356 Bonvadis® Cream samples to enhance clinical collaboration and accessibility.
Diabetic Foot Care Website
To raise public awareness of diabetic foot ulcers, Oneness Biotech has launched a diabetic foot care website for patients and healthcare professionals. This platform compiles the latest treatment knowledge and medical information to support patients in preventing and treating diabetic foot ulcers. The platform also provides physician consultation services and collaborates with pharmacies of major medical centers to provide diabetic foot ulcer care guidelines (V.I.P.D.F.) and real-time medical information. As of December 2024, we have accumulated partnerships with 360 medical institutions.
Affordability of Medicaments
Ensuring that people can afford necessary medicines is crucial for achieving global health goals. However, affordability of medicines requires concerted efforts from businesses, governments, and non-profit organizations. As a corporate entity, it is essential for us to effectively manage the costs associated with medicines to ensure that patients can afford treatment. This not only benefits patients but also ensures the sustainability of the business itself.
Reasonable Pricing
Oneness has entrusted an international consulting firm to conduct pricing recommendations analysis for key markets, including insurance companies and healthcare professionals, in order to establish the optimal global pricing range. In the future, the pricing of medicines upon launch in different countries will be determined based on parameters such as each countries’ GDP and income tailored pricing approach, to establish appropriate local medicine pricing.
Health Insurance Benefits
Taiwan's National Health Insurance system ensures that the public can receive comprehensive medical care. FESPIXON® cream a new domestic pharmaceutical product, is the only prescription drug approved by the Ministry of Health and Welfare for the treatment of diabetic foot ulcers (DFU). Its novel mechanism promotes healing by regulating M1/M2 macrophages and rebalancing the wound microenvironment. On August 1, 2023, it was approved by the National Health Insurance Administration for inclusion in national health insurance coverage. This allows eligible DFU patients to receive early treatment with FESPIXON® cream, promoting wound healing, reducing the risk of ulcer deterioration and amputation, and providing the best possible public healthcare for diabetic patients.
Long-term Donation Program
Oneness announced the "Medical Subsidy Policy for Low-income DFU Patients." Under this program, low-income patients will receive “FESPIXON® cream” free of charge to promote the healing of foot ulcers, thereby reducing the need for amputation and preventing disability. In 2021, 6 low-income patients were subsidized. In 2022, a total of 17 low-income patients have been subsidized. From 2021 to 2023, a total of 28 low-income patients have been subsidized. In 2024, one low-income patient applied for support and was provided with one tube of FESPIXON® Cream.
※The above content is taken from the ESG Report
